The CE mark also allows Medtronic’s automated insulin delivery system to be used during pregnancy and by children as young as two.

About the MiniMed 780G system The MiniMed 780G system is the most advanced insulin pump system from Medtronic, currently approved for the treatment of type 1 diabetes in people aged 7 to 80 years.

Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users PR Newswire - Fri Jun 23, 2023 ...

DUBLIN, June 2, 2021 /CNW/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for 4,120 individuals on the MiniMed™ 780G system, a ...

DUBLIN and SAN DIEGO, June 23, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the ...

Medtronic’s MiniMed 780G system has received European CE Mark approval to expand the indications for use by people aged two years and above, during pregnancy, and for those with type 2 insulin ...

Medtronic plc MDT recently announced the receipt of the CE Mark for its next generation closed loop insulin pump system, MiniMed 780G, for the treatment of type 1 diabetes in the age range of 7 to ...

Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes ...

At the same time, the company pointed to real-world 780G data from more than 26,400 users with Type 2 diabetes, showing a time below range of less than 1%. Medtronic said it is also working with ...

DUBLIN and SAN DIEGO, June 23, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on ...